PEG-asparaginase is used as a treatment for Philadelphia-negative acute lymphoblastic leukemia. In pediatric studies, triglycerides (TGs) were affected more by PEG-asparaginase than by native L-asparaginase (10.0% vs. 5.5%). We conducted a retrospective study to determine the safety of re-challenging adult patients with PEG-asparaginase after experiencing an episode of severe hypertriglyceridemia (>1000 mg/dl or 11.4 mmol/L). The incidence of hypertriglyceridemia associated with PEG-asparaginase in adult patients was high (67.5%). Therefore, checking TGs at baseline and monitoring levels while receiving PEG-asparaginase need to be considered and studied in prospective studies. However, in patients with hypertriglyceridemia not complicated by acute pancreatitis, re-challenging is safe once TG levels normalize.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928666 | PMC |
| http://dx.doi.org/10.1002/jha2.607 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bone Health ECHO Case Report: Orbital Inflammation after Zoledronate Infusion.
J Clin Densitom
October 2024
University of California, San Diego, Division of Endocrinology, Diabetes and Metabolism, San Diego, CA, USA; Veteran's Affairs San Diego, Division of Endocrinology, San Diego, CA, USA.
Prior to the initiation of intravenous bisphosphonate therapy for osteoporosis, the impact on ocular health is not routinely discussed with patients. This is due to the scarcity of data on the association between bisphosphonates and ocular side effects, resulting in lack of provider awareness to effectively counsel patients. Furthermore, there is little consensus among clinicians on the safety of re-challenging with intravenous bisphosphonate treatment following ocular complications.
View Article and Find Full Text PDFEfficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors.
Cancer Manag Res
July 2024
Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
Background: We aim to evaluate the efficacy and safety of anti-PD1 rechallenge in combination with chemotherapy in patients with metastatic nasopharyngeal carcinoma (mNPC) who have progressed on prior anti-PD1 therapy.
Patients And Methods: We enrolled patients with mNPC who received chemotherapy combined with PD-1 immune-checkpoint inhibitors (ICIs) or chemotherapy alone after prior progression of anti-PD1 therapy. The primary endpoint was progress-free survival (PFS), and the secondary endpoints included overall survival (OS), disease control rate (DCR) and objective response rate (ORR).
Therapeutic effects of orally administration of viable and inactivated probiotic strains against murine urinary tract infection.
J Food Drug Anal
December 2023
Department of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University, Taichung 40249, Taiwan.
Article Synopsis
- Urinary tract infections (UTIs) are common bacterial infections that can lead to serious health issues, and specific probiotic strains are suggested for their management and mitigating antibiotic resistance.
- Heat-killed probiotics, especially those producing lactoferrin (LF), show promise against UTIs, although the effectiveness of these inactivated probiotics is still being investigated.
- A study tested the antibacterial properties of heat-killed LF-expressing probiotics and found them to be more effective than natural probiotics in lab tests, followed by an in vivo trial in mice to evaluate their therapeutic potential against UTIs.
Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer.
Front Immunol
November 2023
Division of Medical Oncology, Dalian Municipal Central Hospital, Dalian, China.
With the rapidly evolving of immune checkpoint inhibitors (ICIs), it has shown remarkable clinical benefits in treating various cancers. However, immune-related adverse events (irAEs) remain a significant challenge in the management of patients undergoing immunotherapy. There are limited data about immunotherapy re-challenge in patients with renal clear cell cancer who had irAE in the initial ICI therapy.
View Article and Find Full Text PDFEfficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study.
Lung Cancer
October 2023
Department of Respiratory Medicine, TaiZhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China. Electronic address:
Background: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) show good selectivity for classical EGFR mutated and EGFR T790M mutated non-small cell lung cancer (NSCLC). However, resistance inevitably occurs to third-generation EGFR-TKI. This study describes the real-world characteristics, efficacy, and safety of treating post-progression NSCLC with 160 mg of furmonertinib (in combination with or without anti-angiogenic agents and chemotherapy) with third-generation EGFR-TKIs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!